RPID News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

RP

Volume

355.46K

Next Earnings

November 6th

Loading chart

RP

RPIDRapid Micro Biosystems, Inc. Class A Common Stock

RPID

Pay with—

Available Balance0.00

RP

Mkt Cap

$42.4M

Volume

355.46K

Next Earnings

November 6th

Chart Financials Earnings News About Insider Filings

Rapid Micro Biosystems Announces Pricing of Up to Approximately $32 Million Underwritten OfferingRapid Micro Biosystems (RPID) announced a pricing of an underwritten offering of 3.58 million shares of Class A common stock at $1.955 per share, combined with Series A and Series B warrants. Bain Capital Life Sciences and Armistice Capital are investing approximately $9.8 million, with potential additional proceeds of $21.7 million if all warrants are exercised. The offering is expected to close on May 20, 2026.GlobeNewswire Inc. · May 19, 2026

Rapid Micro Biosystems to Present at 44th Annual J.P. Morgan Healthcare ConferenceRapid Micro Biosystems (Nasdaq: RPID) announced it will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026. The company provides automation solutions for pharmaceutical manufacturing and quality control testing, with its flagship Growth Direct system modernizing microbial quality control workflows. The presentation will be webcast live on the company's investor relations website.GlobeNewswire Inc. · Jan 7, 2026

Rapid Micro Biosystems Reports Third Quarter 2025 Financial Results; Announces Record Multi-System Customer Order and Raises Full-Year Revenue and System Placement GuidanceRapid Micro Biosystems reported Q3 2025 revenue of $7.8 million, a 3% growth from 2024. The company received a record multi-system order from a Top 20 global biopharma customer and raised its full-year revenue guidance to at least $33.0 million.GlobeNewswire Inc. · Nov 7, 2025

Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Rapid Micro Biosystems, Inc. (RPID) announced the grant of 160,000 restricted stock units and 250,000 stock options to a new employee as a material inducement to employment. The equity awards are subject to vesting conditions and were approved by the company's independent directors.GlobeNewswire Inc. · Jun 13, 2025

Rapid Micro Biosystems Announces Appointment of Dr. Dafni Bika to Board of DirectorsRapid Micro Biosystems, an innovative life sciences technology company, has welcomed Dr. Dafni Bika to its Board of Directors. Dr. Bika brings over 25 years of experience in pharmaceutical development and manufacturing, which will contribute to the company's growth as it continues to establish its Growth Direct platform as the industry standard for automating pharmaceutical QC testing.GlobeNewswire Inc. · May 27, 2025

Pharmaceutical Sterility Testing Market to Drive Revenue to USD 3.79 Billion by 2032 | CAGR 11.58%The pharmaceutical sterility testing market is growing rapidly due to increasing demand for safe and effective pharmaceutical products, advancements in testing technologies, and the rising focus on biopharmaceuticals. The market is expected to reach $3.79 billion by 2032, driven by stringent regulations, the need for sterility testing in new therapies, and the shift towards in-house testing.GlobeNewswire Inc. · Nov 15, 2024

Rapid Micro Biosystems Reports Third Quarter 2024 Financial ResultsRapid Micro Biosystems reported record third quarter 2024 revenue of $7.6 million, a 24% increase compared to the prior year. The company placed seven Growth Direct® systems and achieved positive gross margins of 8%, a significant improvement. The company reaffirmed its full-year 2024 revenue guidance of at least $27 million.GlobeNewswire Inc. · Nov 1, 2024

Rapid Micro Biosystems Reports Second Quarter 2024 Financial ResultsRapid Micro Biosystems reported strong Q2 2024 results, with 32% revenue growth, improved gross margins, and announced an operational efficiency program to achieve positive cash flow. The company reaffirmed its full-year 2024 revenue guidance of at least $27 million.GlobeNewswire Inc. · Aug 2, 2024

Rapid Micro Biosystems, Inc. (RPID) Reports Q1 Loss, Tops Revenue EstimatesRapid Micro Biosystems (RPID) delivered earnings and revenue surprises of -6.90% and 0.74%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?Zacks Investment Research · May 3, 2024

Rapid Micro Biosystems Reports First Quarter 2024 Financial ResultsReports first quarter 2024 total revenue of $5.6 million, representing growth of 11% compared to first quarter 2023GlobeNewswire Inc. · May 3, 2024

to start trading

RP

RPIDRapid Micro Biosystems, Inc. Class A Common Stock

RPID

Pay with—

Available Balance0.00

Your PositionYou don't own any RPID yet.

Related Tickers

Earnings